ESMO Media Releases

More than half of patients diagnosed with advanced non-small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the last five years, reveal real-world data from a Spanish national registry study reported at the European Lung Cancer Congress (ELCC), 30 March-2 April 2022.

The European Lung Cancer Congress 2022 (ELCC), the annual event dedicated to advancing the science, disseminating education and improving the practice of lung cancer specialists worldwide, will be held as a virtual meeting. 

Original data presentations by the authors of the OlympiA and PEARLS/KEYNOTE-091 trials will be followed by critical analysis and discussion with a panel of renowned experts.

ESMO announces a new series of resources designed to guide physicians in areas of oncological practice not covered by guidelines, where current evidence is insufficient to evenly inform clinical decision-making

The ESMO Targeted Anticancer Therapies Congress 2022, designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies will be held as a virtual meeting.

Open-source approach leveraging ESMO tools can inform sustainable healthcare spending to benefit national populations worldwide

Death rates from ovarian cancer are predicted to fall by 17% in 2022 in the UK and by 7% in EU countries in 2022 compared to 2017

The ESMO Sarcoma & GIST Symposium 2022, will be held as a virtual event.

The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.

Results of the ESMO Women for Oncology monitoring and authorship studies

The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology.